Bronchiolitis obliterans: Pathogenesis, prevention, and management

American Journal of the Medical Sciences

Volumn 315, Issue 3, 1998, Pages 161-178

  Paradis, Irvin ^a  

^a INTEGRIS Nazih Zuhdi Transplant Institute   (United States)

Author keywords

Bronchiolitis obliterans; Bronchiolitis obliterans syndrome; Lung transplantation

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; GROWTH FACTOR; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; OKT 3; T LYMPHOCYTE RECEPTOR; TACROLIMUS; THYMOCYTE ANTIBODY;

AIRWAY OBSTRUCTION; ANTIGEN PRESENTING CELL; BACTERIAL PNEUMONIA; BRONCHIOLITIS; BRONCHITIS; CLINICAL TRIAL; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; GRAFT INFECTION; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG TRANSPLANTATION; MYCOSIS; NONHUMAN; RESPIRATORY EPITHELIUM; T LYMPHOCYTE;

EID: 0031918551     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199803000-00005     Document Type: Conference Paper

References (165)

1. Hosenpud JD, Bennett LE, Keck BM, Fiol B, Novick RJ. The registry of the International Society for Heart and Lung Transplantation. Fourteenth Official Report - 1997. J Heart Lung Transplant. 1997;6:691-712.
2. Paradis I, Yousem S, Griffith B. Airway obstruction and bronchiolitis obliterans after lung transplantation. Bronchiolitis. Clin Chest Med. 1993;14:751-63.
3. Yousem SA, Berry GJ, Cagle PT, Chamberlain D, Hussian AN, Hruban RH, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft reflection: Lung Rejection Study Group. J Heart Lung Transplant. 1996;15:1-15.
4. Cooper JD, Billingham M, Egan T, Hertz MI, Higenbottam T, Lynch J, et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant. 1993;12:713-6.
5. Valentine VG, Robbins RC, Berry GJ, Patel HR, Reichenspurner H, Reitz BA, et al. Actuarial survival of heart-lung and bilateral sequential lung transplant recipients with obliterative bronchiolitis. J Heart Lung Transplant. 1996;15:371-83.
6. Tullius SG, Tilney NL. Both alloantigen-dependent and - independent factors influence chronic allograft rejection. Transplantation. 1995;59:313-8.
7. Tambur AR, Gebel HM. Alloantigen processing and presentation. J Heart Lung Transplant. 1995;14:1031-7.
8. Halloran PF, Miller LW. In vivo immunosuppressive mechanisms. J Heart Lung Transplant. 1996;15:959-71.
9. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK 506. Immunol Today. 1992;13:136-42.
10. Barnes PJ. Mechanisms of action of glucocorticoids in asthma. Am J Respir Crit Care Med. 1996;154:821-827.
11. Kirk AD, Harlan DM, Armstrong NN, Davis TA, Doug Y, Gray GS, et al. CTLA4-Ig and anti-CD 40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A. 1997;94:8789-94.
12. Geist LJ, Monick MM, Stinski MF, Hunninghake GW. The immediate early genes of human cytomegalovirus upregulate expression of the interleukin-2 and interleukin-2 receptor genes. Am J Respir Cell Mol Biol. 1991;5:292-6.
13. Geist LJ, Monick MM, Stinski MF, Hunninghake GW. Cytomegalovirus immediate early genes prevent the inhibitory effect of cyclosporine A on interleukin 2 gene expression. J Clin Invest. 1992;90:2136-40.
14. Iwamoto GK, Monick MM, Clark BD, Auron PE, Stinski MF, Hunninghake GW. Modulation of interleukin 1 expression by the immediate early genes of human cytomegalovirus. J Clin Invest. 1990;85:1853-7.
15. Geist LJ, Monick MM, Stinski MF, Hunninghake GW. The immediate early genes of human cytomegalovirus upregulate tumor necrosis factor-α gene expression. J Clin Invest. 1994;93:474-8.
16. Geist LJ, Hopkins HA, Dai LY, He B, Monick MM, Hunninghake GW. Cytomegalovirus modulates transcription factors necessary for the activation of the tumor necrosis factor-α promoter. Am J Respir Cell Mol Biol. 1997;16:31-7.
17. Palace GP, Del Vecchio PJ, Horgan MJ, Malik AB. Release of tumor necrosis factor after pulmonary artery occlusion and reperfusion. Am Rev Respir Dis. 1993;147:143-7.
18. Serrick C, Adoumie R. Giaid A, Shennib H. The early release of interleukin-2, tumor necrosis factor-α and interferon-δ after ischemia reperfusion injury in the lung allograft. Transplantation. 1994;58:1158-62.
19. Serrick C, La Franchesca S, Giaid A, Shennib H. Cytokine interleukin-2, tumor necrosis factor-α and interferon-δ release after ischemia/reperfusion injury in a novel lung autograft animal model. Am J Respir Crit Care Med. 1995;152:277-82.
20. Okada M, Yamashita C, Okada M, Okada K. Contribution of endothelin-1 to warm ischemia/reperfusion injury of the rat lung. Am J Respir Crit Care Med. 1995;152:2105-10.
21. Michael J R, Markewitz BA. Endothelins and the lung. Am J Respir Crit Care Med. 1996;154:555-81.
22. Shennib H, Serrick C, Saleh D, Adoumie R, Stewart DJ, Giaid A. Alterations in bronchoalveolar lavage and plasma endothelin-1 levels early after lung transplantation. Transplantation. 1995;59:994-8.
23. McLarty AJ, Miller VM, Tazelaar HD, McGregor CGA. Bronchial contractions in transplanted lungs. Influence of denervation, acute rejection, and the bronchial epithelium. J Thorac Cardiovasc Surg. 1993;106:797-804.
24. Scherstén H, Aarnio P, Burnett JC, McGregor CGA, Miller VM. Endothelin-1 in bronchoalveolar lavage during rejection of allotransplanted lungs. Transplantation. 1994;57:159-61.
25. Aarnio P, Hämmäinen P, Fuhrquist F, Harjula A. Endothelin content of bronchoalveolar lavage fluid from allotransplanted pigs is increased during immodified rejection. J Thorac Cardiovasc Surg. 1994;107:216-9.
26. Serrick C, Giaid A, Reis A, Shennib H. Prolonged ischemia is associated with more pronounced rejection in the lung allograft. Ann Thorac Surg. 1997;63:202-8.
27. Shiraishi T, Mizuta T, DeMeester SR, Ritter JH, Swanson PE, Wick MR, et al. Effect of ischemic injury on subsequent rat lung allograft rejection. Ann Thorac Surg. 1995;60:947-51.
28. Taylor PM, Rose ML, Yacoub MH. Expression of MHC antigens in normal human lungs and transplanted lungs with obliterative bronchiolitis. Transplantation. 1989;48:506-10.
29. Milne DS, Gascoigne AD, Wilkes J, Sviland L, Ashcroft T, Malcolm AJ, Corris PA. MHC Class II and ICAM-1 expression and lymphocyte subsets in transbronchial biopsies from lung transplant recipients. Transplantation. 1994;57:1762-6.
30. Yousem SA, Burke CM, Billingham ME. Pathologic pulmonary alterations in long-term human heart-lung transplantation. Hum Pathol. 1985;16:911-23.
31. Yousem SA, Paradis IL, Dauber JH, Zeevi A, Duquesnoy RJ, Richard DC, et al. Pulmonary arteriosclerosis in long-term human heart-lung transplant recipients. Transplantation. 1989;47:564-9.
32. Kawai A, Paradis IL, Keenan RJ, Yamazaki K, Yousem SA, Ohori NP, et al. Chronic rejection in heart-lung transplant recipients: the relationship between obliterative bronchiolitis and coronary artery disease. Transplant Proc. 1995;27:1288-9.
33. Ohori NP, Iacono AT, Grgurich WF, Yousem SA. Significance of acute bronchitis/bronchiolitis in the lung transplant recipient. Am J Surg Pathol. 1994;18:1192-1204.
34. Tazelaar HD. Perivascular inflammation in pulmonary infections: implications for the diagnosis of lung rejection. J Heart Lung Transplant. 1991;10:437-41.
35. Yousem SA, Duncan SR, Griffith BP. Interstitial and airspace granulation tissue reactions in lung transplant recipients. Am J Surg Pathol. 1992;16:877-84.
36. Milne DS, Gascoigne AD, Ashcroft T, Sviland L, Malcolm AJ, Corris PA. Organizing pneumonia following pulmonary transplantation and the development of obliterative bronchiolitis. Transplantation. 1994;57:1757-62.
37. Siddiqui MT, Garrity ER, Husain AN. Bronchiolitis obliterans organizing pneumonia-like reactions: a nonspecific response or an atypical form of rejection or infection in lung allograft recipients. Hum Pathol. 1996;27:714-9.
38. King TE, ed. Clinics in Chest Medicine: Bronchiolitis. Philadelphia: WB Saunders; 1993;14:607-771.
39. Yousem SA. Lymphocytic bronchitis/bronchiolitis in lung allograft recipients. Am J Surg Pathol. 1993;17:491-6.
40. Ross DJ, Marchevsky A, Kramer M, Kass RM. "Refractoriness" of airflow obstruction associated with isolated lymphocytic bronchiolitis/bronchitis in pulmonary allografts. J Heart Lung Transplant. 1997;16:832-8.
41. Girgis RE, Tu I, Berry GJ, Reichenspurner H, Valentine VG, Conte JV, et al. Risk factors for the development of obliterative bronchioitis after lung transplantation. J Heart Lung Transplant. 1996;15:1200-8.
42. Yousem SA, Curley JM, Dauber J, Paradis I, Rabinowich H, Zeevi A, et al. HLA-Class II antigen expression in human heart-lung allografts. Transplantation. 1990;49:991-5.
43. Yousem SA, Ray L, Paradis IL, Dauber JH, Griffith BP. Potential role of dendritic cells in brochiolitis obliterans in heart-lung transplantation. Ann Thorac Surg. 1990;49:424-8.
44. Holland VA, Cagle PT, Windsor NT, Noon GP, Greenberg SD, Lawrence EC. Lymphocyte subset populations in bronchiolitis obliterans after heart-lung transplantation. Transplantation. 1990;50:955-9.
45. Milne DS, Gascoigne A, Wilkes J, Sviland L, Ashcroft T, Pearson ADJ, et al. The immunohistopathology of obliterative bronchiolitis following lung transplantation. Transplantation. 1992;54:748-50.
46. Hruban RH, Beschorner WE, Baumgartner WA, Achuff SC, Traill TA, Marsh BR, et al. Diagnosis of lung allograft rejection by bronchial intraepithelial Leu-7 positive T lymphocytes. J Thorac Cardiovasc Surg. 1988;96:939-46.
47. Clelland C, Higenbottam T, Stewart S, Otulana B, Wreghitt T, Gray J, et al. Bronchoalveolar lavage and transbronchial lung biopsy during acute rejection and infection in heart-lung transplant patients. Studies of cell counts, lymphocyte phenotypes, and expressions of HLA-DR and interleukin-2 receptor. Am Rev Resp Dis. 1993;147:1386-92.
48. DiGiovine B, Lynch JB, Martinez FJ, Flint A, Whyte RI, Iannettoni MD, et al. Bronchoalveolar lavage neutrophilia is associated with obliterative bronchiolitis after lung transplantation: role of IL-8. J Immunol. 1996;157:4194-202.
49. Paradis I, Zeevi A, Duquesnoy R, Hardesty R, Kromos R, Nalesnick M, et al. Immunologic aspects of chronic lung rejection in humans. Transplant Proc. 1988;20:S812-S814.
50. Maurer JR, Gough E, Chamberlain DW, Patterson GA, Grossman RE. Sequential bronchoalveolar lavage studies from patients undergoing double lung and heart-lung transplant. Transplant Proc. 1989;21:2585-7.
51. Rabinowich H, Zeevi A, Yousem SA, Paradis IL, Dauber JH, Kormos R, et al. Alloreactivity of lung biopsy and bronchoalveolar lavage derived lymphocytes from pulmonary transplant patients: correlation with acute rejection and bronchiolitis obliterans. Clin Transplant. 1990;4:376-84.
52. Rabinowich H, Zeevi A, Paradis IL, Yousem SA, Dauber JH, Kormos R, et al. Proliferative responses of bronchoalveolar lavage lymphocytes from heart-lung transplant patients. Transplantation. 1990;49:115-21.
53. Zeevi A, Rabinowich SA, Paradis IL, Dauber JD, Kormos R, Armitage J, et al. Presence of donor-specific alloreactivity in histologically normal lung allografts is predictive of subsequent bronchiolitis obliterans. Transplant Proc. 1991;23:1128-9.
54. Reinsmoen NL, Bolman RM, Savik K, Butters K, Hertz MI. Are multiple immunopathogenetic events occuring during the development of obliterative bronchiolitis and acute rejection? Transplantation. 1993;55:1040-4.
55. Reinsmoen NL, Bolman RM, Savik K, Butters K, Matas AJ, Hertz MI. Improved long-term graft outcome in lung transplant recipients who have donor antigen specific hyporeactivity. J Heart Lung Transplant. 1994;13:30-7.
56. Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M. Cell migration, chimerism, and graft tolerance. Lancet. 1992;339:1579-82.
57. Starzl TE, Demetris AJ, Trucco M, Ramos H, Zeevi A, Rudert WA, et al. Systemic chimerism in human female recipients of male livers. Lancet. 1992;340:876-7.
58. Starzl TE, Demetris AJ, Trucco M, Zeevi A, Ramos H, Terasaki P, et al. Chimerism and donor-specific nonreactivity 27 to 29 years after kidney transplantation. Transplantation. 1993;55:1272-7.
59. McSherry C, Hertz MI, Jackson AM, Butters K, Diko M, Matas AJ, et al. Allogeneic microchimerism and donor antigen-specific hyporeactivity in lung transplant recipients. Clin Transplant. 1995;9:442-9.
60. McSherry C, Jackson A, Hertz MI, Bolman RM, Savik K, Reinsmoen NL. Sequential measurement of peripheral blood allogeneic microchimerism level and association with pulmonary function. Transplantation. 1996;62:1811-8.
61. Knoop C, Andrien M, Defleur V, Antoine M, de Francquen P, Goldman M, et al. Lung rejection occurs in lung transplant recipients with blood chimerism. Transplantation. 1997;64:167-9.
62. Starzl TE, Demetris AJ, Trucco M, Murase N, Ricordi C, Ildstad S, et al. Cell migration and chimerism after whole organ transplantation: the basis of graft acceptance. Hepatology. 1993;17:1127-52.
63. Fontes P, Rao AS, Demetris AJ, Zeevi A, Trucco M, Carroll P, et al. Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet. 1994;344:151-5.
64. Pham SM, Keenan RJ, Rao A, Fontes P, Zeevi A, Kormos RL, et al. A trial of donor bone marrow infusion and thoracic organ transplantation. J Heart Lung Transplant. 1996;15:S95.
65. Zeevi A, Pham S, Pavlick M, Keenan R, Rad A, Fontes P, et al. Donor-specific bone marrow infusion in lung transplant recipients: the impact on immune modulation and delayed graft rejection. J Heart Lung Transplant. 1997;16:A69.
66. Paradis IL, Marrari M, Zeevi A, Duquesnoy RJ, Griffith BP, Hardesty RL, et al. HLA phenotype of lung lavage cells following heart-lung transplantation. J Heart Transplant. 1985;4:422-5.
67. Sporn MB, Roberts AB. Peptide growth factors are multifactorial. Nature. 1988;332:217-9.
68. Nicod LP, Habre FE, Dayer JM, Boehringer N. In terleukin-10 decreases tumor necrosis factor α and β in alloreactions induced by human lung dendritic cells and macrophages. Am J Respir Cell Mol Biol. 1995;13:83-90.
69. Humbert M, Delattre RM, Fattal S, Rain B, Cerrina J, Dartevelle P, et al. In situ production of interleukin-6 within human lung allografts displaying rejection or cytomegalovirus pneumonia. Transplantation. 1993;56:623-7.
70. Ross DJ, Yeh AY, Nathan SD, Toyoda M, Galera O, Marchevsky A, et al. Differential soluble interleukin-2R levels in bilateral bronchoalveolar lavage after lung transplantation. J Heart Lung Transplant. 1994;13:972-9.
71. Humbert M, Roux-Lombard P, Cerrina J, Magnan A, Simonneau G, Dartevelle P, et al. Soluble TNF receptors (TNF-sR55 and TNF-sR75) in lung allograft recipients displaying cytomegalovirus pneumonia. Am J Respir Crit Care Med. 1994;149:1681-5.
72. Magnan A, Meye JL, Reynaud M, Thomas P, Capo C, Garbe L, et al. Monitoring of alveolar macrophage production of tumor necrosis factor-alpha and interleukin-6 in lung transplant recipients. Am J Respir Crit Care Med. 1994;150:684-9.
73. Magnan A, Mege JL, Escallier JC, Brisse J, Capo C, Reynaud M, et al. Balance between alveolar macrophage IL-6 and TGF-β in lung-transplant recipients. Am J Respir Crit Care Med. 1996;153:1431-6.
74. Scherstén H, Hedner T, McGregor CGA, Miller VM, Martensson G, Ruse GC, et al. Increased levels of endothelin-1 in bronchoalveolar lavage fluid of patients with lung allografts. J Thorac Cardiovasc Surg. 1996;111:253-8.
75. Shumway SJ, Bolman RM, Bitterman PB. Obliterative bronchiolitis after lung transplantation: a fibroproliferative disorder associated with platelet-derived growth factor. Proc Natl Acad Sci U S A. 1992;89:10385-9.
76. Sundaresan S, Alevy YG, Steward N, Tucker J, Trulock EP, Cooper JD, et al. Cytokine gene transcripts for tumor necrosis factor-α, interleukin-2, and interferon-δ in human pulmonary allografts. J Heart Lung Transplant. 1995;14:512-8.
77. Whitehead BF, Stoehr C, Wu CJ, Patterson G, Burchard EG, Theodore J, et al. Cytokine gene expression in human lung transplant recipients. Transplantation. 1993;56:956-61.
78. Keenan RJ, Zeevi A, Iacono AT, Spichty KJ, Cai JZ, Yousem SA, et al. Efficacy of inhaled cyclosporine in lung transplant recipients with refractory rejection: correlation of intragraft cytokine gene expression with pulmonary function and histologic characteristics. Surgery. 1995;118:385-91.
79. Whitehead BF, Stoehr C, Finkle C, Patterson G, Theodore J, Clayberger C, et al. Distribution of TCRαβ+ and TCRγδ+ lymphocytes in bronchoalveolar lavage from human lung transplant recipients. Transplantation. 1993;56:1031-4.
80. Duncan SR, Valentine V, Roglic M, Elias DJ, Pekny KW, Theodore J, et al. T-cell receptor biases and clonal proliferations among lung transplant recipients with obliterative bronchiolitis. J Clin Invest. 1996;97:2642-50.
81. Tazelaar HD, Prop J, Nieuwenhuis P, Billingham ME, Wildevuur CRH. Airway pathology in the transplanted rat lung. Transplantation. 1988;45:864-9.
82. Uyama T, Winter JB, Groen G, Wildevuur CRH, Monden Y, Prop J. Late airway changes caused by chronic rejection in rat lung allografts. Transplantation. 1992;54:809-12.
83. Uyama T, Winter JB, Sakiyuma S, Monden Y, Groen G, Prop J. Replacement of dendritic cells in the airways of rat lung allografts. Am Rev Resp Dis. 1993;148:760-7.
84. Sakiyama S, Uyama T, Tanida N, Fukumota T, Nagasawa H, Himeno K, et al. Pathogenesis of late airway changes in long-term surviving lung allografts. Am J Respir Crit Care Med. 1994;150:1137-41.
85. Lee AGI, Wagner FM, Giaid A, Chen MF, Hamid Q, Serrick C, et al. Immunohistochemical characterization of inflammatory and proliferative events during chronic rejection in rat lung allografts. Transplantation. 1997;64:465-71.
86. Al-Dossari GA, Kshettry VR, Jessurun J, Bolman RM. Experimental large-animal model of obliterative bronchiolitis after lung transplantation. Ann Thorac Surg. 1994;58:34-40.
87. Hertz MI, Jessurun J, King MB, Savik SK, Murray JJ. Reproduction of the obliterative bronchiolitis lesion after heterotopic transplantation of mouse airways. Am J Pathol. 1993;142:1945-51.
88. Al-Dossari GA, Jessurun J, Bolman RM, Kshettry VR, King MB, Murray JJ, et al. Pathogenesis of obliterative bronchiolitis. Possible roles of platelet-derived growth factor and basic fibroblast growth factor. Transplantation. 1995;59:143-5.
89. Boehler A, Chamberlain D, Kesten S, Slutsky AS, Liu S, Keshavjee S. Lymphocytic airway infiltration as a pre-cursor to fibrous obliteration in a rat model of bronchiolitis obliterans. Transplantation. 1997;64:311-7.
90. Morris R, Huang XH, Shorthouse R, Reichenspurner H, Adams B, Berry G. Use of cyclosporine(CsA), mycophenolic acid (MPA), rapamycin (RPM), leflunomide (LFM) or deoxyspergualin (DSG) for prevention and treatment of obliterative airway disease in new animal models. J Heart Lung Transplant. 1995;14:865.
91. Koskinen PK, Kallio EA, Krebs R, Lemström KB. A dose dependent inhibitory effect of cyclosporine A on obliterative bronchiolitis of rat tracheal allografts. Am J Respir Crit Care Med. 1997;155:303-12.
92. Winter JB, Gouw ASH, Groen M, Wildevuur C, Prop J. Respiratory viral infections aggravate airway damage caused by chronic rejection in rat lung allografts. Transplantation. 1994;57:418-22.
93. Koskinen PK, Kallio EA, Bruggeman CA, Lemström KB. Cytomegalovirus infection enhances experimental obliterative bronchiolitis in rat tracheal allografts. Am J Respir Crit Care Med. 1997;155:2078-88.
94. Randhawa PS, Shapiro R, Jordan ML, Starzl TE, Demetris AJ. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK 506. Clinical significance and comparison with cyclosporine. Am J Surg Path. 1993;17:60-8.
95. Oguma S, Belle S, Starzl TE, Demetris AJ. A histometric analysis of chronically rejected human liver allografts: insights into the mechanisms of bile duct loss: direct immunologic and ischemic factors. Hepatology. 1989;9:204-9.
96. Freese DK, Snover DC, Sharp HL, Gross CR, Savick SK, Payne WD. Chronic rejection after liver transplantation: a study of clinical, histopathological and immunological features. Hepatology. 1991;13:882-91.
97. Pascoe EA, Barnhart GR, Carter WH, Thompson JA, Hess MI, Hastillo A, et al. The prevalence of cardiac allograft arteriosclerosis. Transplantation. 1987;44:838-9.
98. Uretsky BF, Murali S, Reddy PS, Rabin BS, Lee A, Griffith BP, et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation. 1987;76:827-34.
99. Clark JG, Schwartz DA, Flournoy N. Sullivan KM, Crawford SW, Thomas ED. Risk factors for airflow obstruction in recipeints of bone marrow transplants. Ann Int Med. 1987;107:648-56.
100. Clark JG, Crawford SW, Madtes DK, Sullivan KM. Obstructive lung disease after allogeneic marrow transplantation: clinical presentation and course. Ann Int Med. 1989;111:368-76.
101. Beschorner WE, Saral R, Hutchins GM, Tutschka PJ, Santos GW. Lymphocytic bronchitis associated with graft versus host disease in recipients of bone marrow transplants. N Engl J Med. 1978;299:1030-6.
102. O'Brien KD, Hackman RC, Sale GE, Prentice R, Deeg J, Thomas ED, et al. Lymphocytic bronchitis unrelated to acute graft versus host disease in canine marrow graft recipients. Transplantation. 1984;37:233-8.
103. Narrod J, Kormos R, Armitage J, Hardesty R, Ladowski J, Griffith B. Acute rejection and coronary artery disease in long-term survivors of heart transplantation. J Heart Transplant. 1989;8:418-21.
104. Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation. 1993;55:752-7.
105. Troppmann C, Gillingham KJ, Benedetti E, Almond PS, Gruessner RWG, Najarian JS, et al. Delayed graft function, acute rejection and outcome after cadaver renal transplantation. A multivariate analysis. Transplantation. 1995;59:962-8.
106. McGiffin DC, Savunen T, Kirklin JK, Naftel DC, Bourge RC, Paine TD, et al. Cardiac transplant coronary artery disease. A multivariable analysis of pretransplantation risk factors for disease development and morbid events. J Thorac Cardiovasc Surg. 1995;109:1081-9.
107. Loebe M, Schüler S, Zais O, Warnecke H, Fleck E, Hetzer R. Role of cytomegalovirus infection in the development of coronary artery disease in the transplanted heart. J Heart Transplant. 1990;9:707-11.
108. Gratton MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA. 1989;261:3561-6.
109. McDonald K, Rector TS, Braunlin EA, Kubo SH, Olivari MT. Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am J Cardiol. 1988;64:359-62.
110. Zhou YF, Leon MB, Waclawiw MA, Popma JJ, Finkel T, Epstein SE. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med. 1996;335:624-30.
111. Rubin RH, Tolkoff-Rubin NE, Oliver D, Rota TR, Hamilton J, Betts RF, et al. Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation. Transplantation. 1985;40:243-9.
112. Von Willebrand E, Pettersson E, Ahonen J, Häyry P. CMV infection, class II antigen expression, and human kidney allograft rejection. Transplantation. 1996;42:364-7.
113. O'Grady JG, Alexander GJM, Sutherland S, Donaldson PT, Harvey F, Portmann B, et al. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent cofactors in pathogenesis of vanishing bile duct syndrome after liver transplantation. Lancet. 1988;2:302-5.
114. Armitage JO. Bone marrow transplantation. N Engl J Med. 1994;330:827-38.
115. Van Dorp WT, Jonges E, Bruggeman CA, Daha MR, Van Es LA, Van der Woude FJ. Direct induction of MHC Class I, but not Class II, expression on endothelial cells by cytomegalovirus infection. Transplantation. 1989;48:469-72.
116. Khoury El, Pereira L, Greenspun FS. Induction of HLA-DR expression on thyroid follicular cells by cytomegalovirus infection in vitro. Evidence for a dual mechanism of induction. Am J Pathol. 1991;138:1209-23.
117. Halloran P, Aprile M, Farewell V for the Ontario Renal Transplant Research Group. Factors influencing early renal function in cadavar kidney transplants: a case control study. Transplantation. 1988;45:112-27.
118. Howard TK, Klintmalm GBG, Cofer JB, Husberg BS, Goldstein RM, Gonwa TA. The influence of preservation injury on rejection in the hepatic transplant recipient. Transplantation. 1990;49:103-7.
119. Shackleton CR, Ettinger SL, McLoughlin MG, Scudamore CH, Miller RR, Keown PA. Effect of recovery from ischemic injury on Class I and Class II MHC antigen expression. Transplantation. 1990;49:641-4.
120. Opelz G (Collaborative Transplant Study). Correlation of HLA matching with kidney graft survival in patients with or without cycylosportine treatment. Transplantation. 1985;40:240-243.
121. Opelz G, Mytilineos J, Scherer S, Dunckley H, Trejant J, Chapman J, et al. Analysis of HLA-DR matching in DNA-typed cadaver kidney transplants. Transplantation. 1993;55:782-5.
122. Held PJ, Kahan BD, Hunsicker LG, Liska D, Wolfe RA, Port FK, et al. The impact of HLA mismatches on the survival of first cadaveric kidney transplants. N Engl J Med. 1994;331:765-70.
123. Sanfilippo F. HLA matching in renal transplantation. Editorial. N Engl J Med. 1994;331:803-5.
124. Opelz G, Wujciak T for the Collaborative Transplant Study. The influence of HLA compatability on graft survival after heart transplantation. N Engl J Med. 1994;330:816-9.
125. Morris PJ. HLA matching and heart transplantation. Editorial. N Engl J Med. 1994;330:857-8.
126. Reinsmoen NL, Jackson A, McSherry C, Ninova D, Wiesner RH, Kondo M, et al. Organ specific patterns of donor antigen-specific hyporeactivity and peripheral blood allogeneic microchimerism in lung, kidney, and liver transplant recipients. Transplantation. 1995;60:1546-54.
127. Vincenti F, Duca RM, Amend W, Perkins HA, Cochrum KC, Feduska NJ, et al. Immunologic factors determining survival of cadaver-kidney transplants. The effect of HLA serotyping, cytotoxic antibodies and blood transfusions on graft survival. N Engl J Med. 1978;299:793-8.
128. Opelz G, Terasaki P. Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med. 1978;299:799-803.
129. Flye MW, Burton K, Mohanakumar T, Brennan D, Keller C, Goss JA, et al. Donor-specific transfusions have long-term beneficial effects for human renal allografts. Transplantation. 1995;60:1395-1401.
130. Hadley GA, Anderson CB, Mohanakumar T. Selective loss of functional antidonor cytotoxic T cell precursors following donor specific blood transfusions in long-term renal allograft recipients. Transplantation. 1992;54:333-7.
131. Sivasai KSR, Alevy YG, Duffy BF, Brennan DC, Singer GG, Shenoy S, et al. Peripheral blood microchimerism in human liver and renal transplant recipients. Transplantation. 1997;65:427-32.
132. Schutt HJ, Hundrieser J, Ringe B, Pichlmayr R. Donor-type microchimerism associated with graft rejection eight years after liver transplantation. N Engl J Med. 1994;330:646-47.
133. Molleston JP, Alevy YG, Sivasai KSR, Mohanakumar T, Howard TK. Evidence that pediatric liver transplant recipients may undergo late rejection episodes in spite of donor specific microchimerism. Transplantation. 1996;61:656-7.
134. Jonsson JR, Hogan PG, Thomas R, Steadman C, Clouston AD, Balderson GA, et al. Peripheral blood chimerism following human liver transplantation. Hepatology. 1997;25:1233-6.
135. Burke CM, Theodore J, Dawkins KD, Yousem SA, Blank N, Billingham ME, et al. Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation. Chest. 1984;86:824-9.
136. Burke CM, Baldwin JC, Morris AJ, Shumway NE, Theodore J, Tazelaar HD, et al. Twenty-eight cases of human heart-lung transplantation. Lancet. 1986;1:517-9.
137. Glanville AR, Baldwin JC, Burke CM, Theodore J, Robin ED. Obliterative bronchiolitis after heart-lung transplantation: apparent arrest by augmented immunosuppression. Ann Int Med. 1987;107:300-4.
138. Allen MD, Burke CM, McGregor CGA, Baldwin JC, Jamieson SW, Theodore J. Steroid-responsive bronchiolitis after human heart-lung transplantation. J Thorac Cardiovasc Surg. 1987;92:449-51.
139. 3 after unilateral lung transplantation: a plea for multi-center immunosuppressive trials. Chest. 1996;109:870-3.
140. Kesten S, Rajagopalan N, Maurer J. Cytolytic therapy for the treatment of bronchiolitis obliterans syndrome following lung transplantation. Transplantation 1996;61:427-30.
141. Snell GI, Esmore OS, Williams TJ. Cytolytic therapy for the bronchiolitis obliterans syndrome complicating lung transplantation. Chest. 1996;109:874-8.
142. Keenan RJ, Konishi H, Kawai A, Paradis IL, Nunley DR, Iacono AT, et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg. 1995;60:580-5.
143. Speich R, Boehler A, Thurnheer R, Weder W. Salvage therapy with mycophenolate mofetil for lung transplant bronchiolitis obliterans: importance of dose. Transplantation. 1997;64:533-5.
144. Dusmet M, Maurer J, Winton T, Kesten S. Methotrexate can halt the progression of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant. 1996;15:948-54.
145. Achkar A, Laaban JP, Couetil JP, Heshmati F, Doré MF, Molina T, et al. Extracorporeal photochemotherapy (ECP) for bronchiolitis obliterans (BO) after heart-lung (HLTX) and lung transplantation (LTX). J Heart Lung Transplant. 1997;16:A69.
146. Afolabi OA, Parry G, Healy MD, Corris PA, Dark JH. The role of total lymphoid irradiation (TLI) in the treatment of obliterative bronchiolitis - 2 years on. J Heart Lung Transplant. 1996;15:8102.
147. Iacono AT, Keenan RJ, Duncan SR, Smaldone GC, Dauber JH, Paradis IL, et al. Aerosolized cyclosporine in lung recipients with refractory chronic rejection. Am J Respir Crit Care Med. 1996;153:1451-5.
148. Paradis IL. Infection after lung transplantation. In: Cooper DKC, Miller LW, Patterson GA, eds. The Transplantation and Replacement of Thoracic Organs. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1997:527-42.
149. Dauber JH, Paradis IL, Dummer JS. Infectious complications in pulmonary allograft recipients. Clin Chest Med. 1990;11:291-308.
150. Scott JB, Higenbottam TW, Sharples L, Clelland CA, Smyth RL, Stewart S, et al. Risk factors for obliterative bronchiolitis in heart-lung transplant recipients. Transplantation. 1991;51:813-7.
151. Sharples L, Tamm M, McNeil K, Higenbottam TW, Stewart S, Wallwork J. Development of bronchiolitis obliterans syndrome in recipients of heart-lung transplantations - early risk factors. Transplantation. 1996;61:560-6.
152. Yousem SA, Dauber JH, Keenan R, Paradis IL, Zeevi A, Griffith BP. Does histologic acute rejection in lung allografts predict the development of bronchiolitis obliterans? Transplantation. 1991;52:306-9.
153. Bondo K, Paradis IL, Similo S, Konishi H, Komatsu K, Zullo TG, et al. Obliterative bronchiolitis after lung and heart-lung transplantation: an analysis of risk factors and management. J Thorac Cardiovasc Surg. 1995;110:4-14.
154. Keller CA, Cagle PT, Brown RW, Noon G, Frost AE. Bronchiolitis obliterans in recipients of single, double, and heart-lung transplantation. Chest. 1995;107:973-80.
155. You X-M, Steinmüller C, Wagner TOF, Bruggeman CA, Haverich A, Steinhoff G. Enhancement of cytomegalovirus infection and acute rejection after allogeneic lung transplantation in the rat: virus-induced expression of major histocompatibility complex Class II antigens. J Heart Lung Transplant. 1996;15:1108-19.
156. Burke CM, Glanville AR, Macoviak JA, O'Connell BM, Tazelaar HD, Baldwin JC, et al. The spectrum of cytomegalovirus infection following human heart-lung transplantation. J Heart Transplant. 1986;5:267-72.
157. Keenan RJ, Lega ME, Dummer JS, Paradis IL, Dauber JH, Rabinowich H, et al. Cytomegalovirus serologie status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation. 1991;51:433-8.
158. Duncan SR, Paradis IL, Yousem SA, Similo SL, Grgurich WF, Williams PA, et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis. 1991;146:1213-5.
159. Ettinger NA, Bailey TC, Trulock EP, Storch GA, Anderson D, Raab S, et al. Cytomegalovirus infection and pneumonitis: impact after isolated lung transplantation. Am Rev Resp Dis. 1993;147:1017-23.
160. Lautenschlager I, Soots A, Krogerus L, Kauppinen H, Saarinen D, Bruggeman C, et al. Effect of cytomegalovirus on an experimental model of chronic renal allograft rejection under triple drug treatment in the rat. Transplanation. 1997;64:391-8.
161. Schreinmakers HHJ, Weder W, Miyoshi S, Harper BD, Shimokawa S, Egan TM, et al. Direct revascularization of bronchial arteries for lung transplantation: An anatomical study. Ann Thorac Surg. 1990;49:44-54.
162. Harjula ALJ, Baldwin JC, Glanville AR, Tazelaar H, Oyer PE, Stinson EB, et al. Human leukocyte antigen compatibility in heart-lung transplantation. J Heart Transplant. 1987;6:162-6.
163. Iwaki Y, Yoshida Y, Griffith BP. The HLA matching effect in lung transplantation. Transplantation. 1993;56:1528-9.
164. Wisser W, Wekerle T, Zlabinger G, Senbaclavaci Ö, Zuckermann A, Klepetko W, et al. Influence of human leukocyte antigen matching on long-term outcome after lung transplantation. J Heart Lung Transplant. 1996;15:1209-16.
165. Kubit V, Soumez-Alpan E, Zeevi A, Paradis IL, Dauber JH, Iacono A, et al. Mixed allogeneic chimerism in lung allograft recipients. Human Pathol. 1994;25:408-12.